

Sélection des publications 2014 de l'équipe 1

- Chevalier X, Ravaud P, Maheu E, Baron G, Rialland A, Vergnaud P, Roux C, Maugars Y, Mulleman D, Lukas C, Wendling D, Lafforgue P, Loeuille D, Foltz V, Richette P; On behalf of the French section of osteoarthritis.
Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial.
Ann Rheum Dis. 2015, 74: 1697-1705

- Club Rhumatismes et Inflammations.
Biologic targeted therapies in pediatric rheumatology.
Joint Bone Spine. 2014, 81 Suppl 1: 2-48

- Coudert B, Pierga PY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupré PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo Riedinger A.
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Lancet Oncol 2014, 15 (13): 1493-1502

- Ducourau E, Ternant D, Lequerré T, Fuzibet P, Le Loët X, Watier H, Goupille P, Paintaud G, Vittecoq O, Mulleman D.
Towards an individualised target concentration of adalimumab in rheumatoid arthritis.
Ann Rheum Dis. 2014 Feb 18. doi: 10.1136/annrheumdis-2013-204971. [Epub ahead of print]

- Dupuis-Girod S, Ambrun A, Decullier E, Samson G, Roux A, Fargeton AE, Rioufol C, Schwiertz V, Disant F, Chapuis F, Donazzolo Y, Paintaud G, Edery P, Faure F.
ELLIPSE Study: A Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
MAbs. 2014, 6 : 794-799

- Gruel Y, Rollin J, Leroux D, Pouplard C.
[Heparin-induced thrombocytopenia: recent data].
[Article in French]
Rev Med Interne. 2014, 35: 174-182.

- Guilleminault L, Azzopardi N, Arnoult C, Sobilo J, Hervé V, Montharu J, Guillon A, Andres C, Herault O, Le Pape A, Diot P, Lemarié E, Paintaud G, Gouilleux-Gruart V, Heuzé-Vourc'h N.
Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system.
J Control Release. 2014, 28 : 344-354

- Guillon-Munos A, Daguet A, Watier H.
Antibody biosimilars; Fears or opportunities? First LabEx MAbImprove industrial workshop, May 28, 2013; Tours, France.
MAbs. 2014, 6 : 805-809

- Hervé V, Rabbe N, Guilleminault L, Paul F, Schlick L, Azzopardi N, Duruisseaux M, Fouquenot D, Montharu J, Redini F, Paintaud G, Lemarié E, Cadranel J, Wislez M, Heuze Vourc'h N.
VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations.
MAbs. 2014, 6 : 1638-1648

- Joubert JM, Gottenberg JE, Paintaud G; participants of round table N°2 of Giens XXIX: Augendre-Ferrante B, Cans C, Cellier D, Chevalier MP, Diaz I, Filipecki J, Kahn JE, Le Men J, Mulleman D, Urbain R, Vasmant D.
Translational Research in Immune and Inflammatory Diseases; What are the Challenges, Expected Advances, and Innovative Therapies?
Thérapie. 2014, 69 : 291-302
- Krens LL, Baas JM, Verboom MC, Paintaud G, Desvignes C, Guchelaar HJ, Gelderblom H.
Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction.
Cancer Chemother Pharmacol. 2014,73 : 1303-1306
- Lajoie L, Congy-Jolivet N, Bolzec A, Gouilleux-Gruart V, Sicard E, Sung HC, Peiretti F, Moreau T, Vié H, Clémenceau B, Thibault G.
ADAM17-Mediated Shedding of FcγRIIIA on Human NK Cells: Identification of the Cleavage Site and Relationship with Activation.
J Immunol. 2014, 192 : 741-751
- Le Moigno L, Ternant D, Paintaud G, Thibault G, Cloarec S, Tardieu M, Lagrue E, Castelnau P.
Encéphalite à anticorps anti-récepteurs N-méthyl-D-aspartate (NMDA-R) : place des immunomodulateurs
Arch Pediatr. 2014, 21 : 620-623
- Leroux D, Hezard N, Lebreton A, Bauters A, Suchon P, de Maistre E, Biron C, Huisse MG, Ternisien C, Voisin S, Gruel Y, Pouplard C.
Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic Expert® HIT) for the diagnosis of heparin-induced thrombocytopenia.
Br J Haematol. 2014, 166: 774-782
- Leveziel N, Pelat T, Watier H, Thullier P, Souied EH.
Detection of Antiranibizumab Antibodies among Patients with Exudative Age-Related Macular Degeneration.
Ophthalmologica. 2014,232: 53-56
- Longuet H, Sautenet B, Gatault P, Thibault G, Barbet C, Marliere JF, Halimi JM, Lebranchu Y, Baron C, Büchler M.
Risk factors for impaired CD4+ T-cell reconstitution following rabbit antithymocyte globulin treatment in kidney transplantation.
Transpl Int. 2014, 27: 271-279
- Mulleman D.
Do immunoglobulin levels and CD4 cell count interact during Rituximab treatment?
Arthritis Rheum. 2014 Jan 27. doi: 10.1002/art.38361. [Epub ahead of print]
- Mulleman D, Thibault G.
Reply to PMID 23918413.
Arthritis Rheum. 2014, 66: 1054-1055
- Pèlegri A, Daguet A, Watier H.
MAbImprove: A French Laboratoire d'excellence (LabEx) dedicated to therapeutic antibodies.
MAbs. 2014, 6 : 803-804
- Pottier J, Watier H.
Unexplained Abuses of Human IgG Subclass Denomination in Antibody Patents.
BioDrugs. 2014, 28: 327-329

- Rajca S, Grondin V, Louis E, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Paintaud G, Piver E, Allez M, Mary JY, Sokol H, Colombel JF, Seksik P.
Alterations in the Intestinal Microbiome (Dysbiosis) as a Predictor of Relapse After Infliximab Withdrawal in Crohn's Disease.
Inflamm Bowel Dis. 2014, 20 : 978-986
- Ternant D, Büchler M, Thibault G, Ohresser M, Watier H, Lebranchu Y, Paintaud G.
Influence of FcγRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients.
Pharmacogenet Genomics. 2014, 24 : 26-34
- Ternant D, Ducourau E, Perdriger A, Corondan A, Le Goff B, Devauchelle-Pensec V, Solau-Gervais E, Watier H, Goupille P, Paintaud G, Mulleman D.
Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis.
Br J Clin Pharmacol. 2014, 78 : 118-128
- Thibault G, Mulleman D.
Direct and indirect rituximab-induced T-cell depletion.
Arthritis Rheumatol. 2014, 66 : 1053
- Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera AP, Pisella PJ, Gueyffier F, Bejan-Angoulvant T.
Cardiovascular events and bleeding risk associated with intravitreal anti-VEGF monoclonal antibodies: Systematic review and meta-analysis
JAMA Ophthalmol. 2014, 132 : 1317-1326
- Vincent M, Teppaz G, Lajoie L, Solé V, Bessard A, Maillason M, Loisel S, Bécharde D, Clémenceau B, Thibault G, Garrigue-Antar L, Jacques Y, Quémener A.
Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.
MAbs. 2014, 6 : 1026-1037.
- Watier H.
Biothérapies, immunothérapies, thérapies ciblées, bioproduits... De quoi faut-il parler ?
Med Sci (Paris). 2014, 30 : 567-75.
- Wendling D, Lukas C, Paccou J, Claudepierre P, Carton L, Combe B, Goupille P, Guillemin F, Hudry C, Miceli-Richard C, Dougados M.
Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis.
Joint Bone Spine. 2014, 81 : 6-14